Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Renal Cell Carcinoma - An Introduction

4. Drivers and Challenges
    4.1 Drivers
          4.1.1 Increasing Geriatric Population
          4.1.2 Quick Diagnosis with Modern Imaging Techniques
          4.1.3 Increasing Risk from Lifestyle Related Factors
          4.1.4 Grants and Tax Credits
    4.2 Challenges
           4.2.1 High Cost
           4.2.2 Lack of Disease History Awareness & Research Participants
           4.2.3 Rising Patent Cliff

5. Renal Cell Carcinoma Drugs Market Overview

6. Major Branded Drugs
    6.1 Sutent
    6.2 Votrient
    6.3 Afinitor
    6.4 Nexavar
    6.5 Inlyta
    6.6 Avastin
    6.7 Proleukin
    6.8 Torisel
    6.9 Opdivo

7. Market Segmentation By Geography
    7.1 North America
    7.2 Europe
    7.3 Asia-Pacific

8. Renal Cell Carcinoma Drugs Pipeline

9. Trends and Developments
    9.1 Positive Outcomes from Clinical Trials Driving RCC Market
    9.2 ADCs - A Novel Treatment Option for RCC

10. Mergers and Acquisitions

11. Competitive Landscape

12. Key Players Analysis
     12.1 Pfizer Inc.
     12.2 F.Hoffmann-La Roche AG
     12.3 Novartis
     12.4 GlaxoSmithKline
     12.5 Bayer AG
     12.6 Bristol-Myers Squibb
     12.7 Merck & Co., Inc.
     12.8 AstraZeneca
     12.9 Eli Lilly & Co.
     12.10 Amgen Inc.